| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -61,550 | -34,721 |
| Depreciation and amortization | 1,336 | 885 |
| Amortization of debt discount | 1,273 | 859 |
| Change in fair value of derivatives | -1,328 | 2,004 |
| Change in fair value of share payable | -381 | -263 |
| Change in fair value of convertible notes | 6,074 | 6,089 |
| Loss from extinguishment of debt | -15,802 | -11,798 |
| Loss from issuance of debt | -2,384 | -773 |
| Amortization of operating lease right-of-use asset | 200 | 130 |
| Stock-based compensation for services | 1,022 | 749 |
| Subtotal of non-cash charges | 17,652 | 7,364 |
| Prepaid expenses and other current assets | 389 | -111 |
| Other non-current assets | -13 | -3 |
| Accounts payable and accrued expenses | 8,855 | 7,534 |
| Related party accounts payable and accrued expenses | 5,389 | 3,564 |
| Lease liabilities | 31 | 39 |
| Net cash used in operating activities | -29,999 | -16,106 |
| Purchase of equipment and construction in progress | 599 | 397 |
| Loan receivable | 311 | - |
| Net cash used in investing activities | -910 | -397 |
| Proceeds from issuance of common shares | 17,304 | 12,442 |
| Proceeds from exercise of warrants | 23 | 23 |
| Proceeds from issuance of notes payable, net | 7,000 | 7,000 |
| Proceeds from issuance of convertible notes payable, net | 12,682 | 5,507 |
| Repayment of notes payable | 259 | 255 |
| Repayment of convertible notes payable | 1,011 | 536 |
| Net cash provided by financing activities | 35,739 | 24,181 |
| Effect of exchange rate changes on cash and cash equivalents | -2,445 | -5,537 |
| Net increase in cash and cash equivalents | 2,385 | 2,141 |
| Cash and cash equivalents at beginning of period | 2,175 | - |
| Cash and cash equivalents at end of period | 4,560 | - |
NORTHWEST BIOTHERAPEUTICS INC (NWBO)
NORTHWEST BIOTHERAPEUTICS INC (NWBO)